| Literature DB >> 28445129 |
Xin Zhan1, Jie Wang2, Shufen Pan3, Caijuan Lu1.
Abstract
A large number of epidemiological studies have provided conflicting results about the relationship between tea consumption and ovarian cancer. This study aimed to clarify the association between tea consumption and ovarian cancer. A literature search of the MEDICINE, Scopus, PubMed, and Web of Science databases was performed in April 2016. A total of 18 (11 case-control and 7 cohort) studies, representing data for 701,857 female subjects including 8,683 ovarian cancer cases, were included in the meta-analysis. A random-effects meta-analysis was used to compute the pooled relative risks (RR), meta regression, and publication bias, and heterogeneity analyses were performed for the included trials. We found that tea consumption had a significant protective effect against ovarian cancer (relative risk [RR] = 0.86; 95% confidence interval [CI]: 0.76, 0.96). The relationship was confirmed particularly after adjusting for family history of cancer (RR = 0.85; 95% CI: 0.72, 0.97), menopause status (RR = 0.85; 95% CI: 0.72, 0.98), education (RR = 0.82; 95% CI: 0.68, 0.96), BMI (RR = 0.85; 95% CI: 0.70, 1.00) , smoking (RR = 0.83; 95% CI: 0.72, 0.93) and Jadad score of 3 (RR = 0.76; 95% CI: 0.56, 0.95) and 5 (RR = 0.74; 95% CI: 0.59, 0.89). The Begg's and Egger's tests (all P > 0.01) showed no evidence of publication bias. In conclusion, our meta-analysis showed an inverse association between tea consumption and ovarian cancer risk. High quality cohort-clinical trials should be conducted on different tea types and their relationship with ovarian cancer.Entities:
Keywords: meta-analysis; ovarian cancer; tea
Mesh:
Substances:
Year: 2017 PMID: 28445129 PMCID: PMC5514950 DOI: 10.18632/oncotarget.16890
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Search strategy and selection of studies
Figure 2Forest plot of studies evaluating the association between tea consumption and risk of ovarian cancer, ES: effect size
Characteristics of the studies included in the meta-analysis
| Study | Year | Country | Study period | No. of cases/size | Exposure range | Adjusted RR (95% CI) | Adjustment for covariates | Jadad score |
|---|---|---|---|---|---|---|---|---|
| Gosvig CF et al. | 2015 | Denmark | 1995–1999 | 382/911 | ≥ 4 cups/day; 0 | 0.81 (0.48–1.42) | Pregnancy (ever/never), number of pregnancies (linear), oral contraceptive use (ever/never), duration of OCP use (linear) | 4 |
| Braem MG et al. | 2012 | Europe | 1992–2000 | 241/330,849 | highest; lowest | 1.07 (0.78, 1.46) | OCP, BMI, smoking status, alcohol consumption, total energy intake, duration of breastfeeding, menopausal status, height, and educational level. | 4 |
| Nagle CM et al. | 2010 | Australia | 2002–2005 | 1,271/1,198 | ≥ 4cups/day; Never | 0.71 (0.52–0.97) | Age, education, parity, hormonal contraceptive use, smoking status (current, ex, or non), fruit consumption, vegetable consumption, coffee consumption, consumption of other types of tea | 3 |
| Tworoger SS et al. | 2008 | USA | 1976–2004 | 507/80,253 | ≥ 2 cups/d; ≤ 1 cup/wk | 0.96 (0.70, 1.30) | Age, parity, OCP use, postmenopausal hormone use, tubal ligation, BMI | 4 |
| Song YJ et al. | 2008 | USA | 2002–2005 | 781/1,263 | ≥1 cup/d; Non | 0.92 (0.63–1.33) | Age, county, year of diagnosis/reference date, race/ethnicity, number of full-term pregnancies, duration of hormonal contraception, education, BMI, smoking, tubal ligation/hysterectomy, family history of breast/ovarian cancer | 3 |
| Steevens J et al. | 2007 | Netherlands | 1986–2000 | 280/62,573 | ≥ 5 cups/d; 1–3 cups/d | 0.65 (0.41, 1.03) | Age, use of oral contraceptives (ever/never) | 4 |
| Silvera SA et al. | 2007 | Canada | 1980–1985 | 264/49,613 | ≥ 4 cups/d; 0 cups/d | 1.07 (0.64, 1.79) | Age, smoking history, pack-years of smoking, alcohol intake, education, BMI, parity, participation in vigorous physical activity, menopausal status, OCP use, energy intake, lactose intake, study center, randomization group | 3 |
| Baker JA et al.. | 2007 | USA | 1982–1998 | 414/828 | ≥ 2 cups/day; 0 | 0.70 (0.51–0.97) | Age, residence, and year of participation | 5 |
| Gates MA et al. | 2007 | USA | 1984–2002 | 577/66,940 | > 2/day; ≤ 1/week (servings) | 0.63 (0.40, 0.99) | Age, duration of OCP use, parity, history of tubal ligation, smoking status, history of postmenopausal hormone use, physical activity, lactose intake, total energy intake | 5 |
| Larsson et al. | 2005 | Sweden | 1987–2004 | 301/61,057 | ≥ 2 cups/day; 0 cups/d | 0.54 (0.31–0.91) | Age (in months); BMI; education; parity; OCP use; intake of total energy; consumption of fruit, vegetables, milk, liquor, beer, wine, and coffee | 5 |
| Jordan et al. | 2004 | Australia | 1990–1993 | 696/786 | ≥ 4 cups/day; 0 cups/d | 1.10 (0.76–1.61) | Age, age squared, BMI, duration of OCP, parity, smoking, alcohol, education, energy intake. | 4 |
| Yen ML et al | 2003 | Taiwan, China | 1993–1998 | 86/369 | Yes; No | 0.79 (0.47–1.32) | Age, income during marriage, and education, number of live births was made on the analysis of age at first pregnancy, number of incomplete pregnancies, breastfeeding, OCP use, intrauterine device use | 4 |
| Goodman et al. | 2003 | USA | 1993–1999 | 164/194 | ≥ 1 cups/week; ≤1 cups/week | 0.99 (0.65–1.51) | Age, ethnicity, OCP, tubal ligation | 4 |
| Tavani et al. | 2001 | Italy | 1992–1999 | 1,031/2,411 | ≥ 1 cups/month; None | 0.90 (0.75–1.08) | Study center, year of interview, age, education, parity, age at menopause, OCP, family history of ovarian/breast cancer, BMI, total energy intake | 5 |
| Kuper et al. | 2000 | USA | 1992–1997 | 549/516 | ≥ weekly; Rarely | 1.06 (0.83–1.36) | Age, center activity | 4 |
| Zheng et al. | 1996 | USA | 1986–1993 | 107/35,369 | ≥ 2 cups/day; Never or monthly | 0.98 (0.50–1.90) | Age at menarche, age at menopause, age at first pregnancy, age, education, smoking status, pack-years smoking, physical activity, fruit/vegetable intake, waist/hip ratio, family history of cancer | 5 |
| La Vechia et al. | 1992 | Italy | 1983–1990 | 742/6,147 | ≥ 1 cups/day; None | 1.2 (1.0–1.4) | Age, area of residence, education, smoking, coffee consumption | 4 |
| Miller et al. | 1987 | USA | 1976–1983 | 290/580 | ≥ 5 cups/day; 0 | 0.50 (0.2–1.0) | Age, race, religion, smoking, alcohol, OCP use, estrogen use, BMI, age at menarche, age at first pregnancy, parity, age at menopause, type of menopause, years of education, geographical location of hospital, year of interview, no. of lifetime non-obstetric hospital admissions. | 3 |
USA: the United States of America, BMI: body mass index, CI: confidence interval, RR: relative risk, OCP: oral contraceptive pill.
Stratified analysis of ovarian cancer in relation to tea consumption according to study characteristics
| Group | No. of studies | RR (95% CI) | ||
|---|---|---|---|---|
| Family history of cancer | ||||
| Yes | 3 | 0.91 (0.76, 1.05) | 0.973 | 0 |
| No | 15 | 0.85 (0.72, 0.97) | 0.003 | 57 |
| Menopause | ||||
| Yes | 5 | 0.89 (0.71, 1.07) | 0.269 | 22.8 |
| No | 13 | 0.85 (0.72, 0.98) | 0.006 | 56.5 |
| Education | ||||
| Yes | 11 | 0.88 (0.74, 1.03) | 0.010 | 56.9 |
| No | 7 | 0.82 (0.68, 0.96) | 0.212 | 28.4 |
| OCP use | ||||
| Yes | 14 | 0.81 (0.71, 0.91) | 0.218 | 21.7 |
| No | 4 | 0.99 (0.72, 1.26) | 0.014 | 71.6 |
| BMI | ||||
| Yes | 8 | 0.87 (0.72, 1.02) | 0.122 | 38.6 |
| No | 10 | 0.85 (0.70, 1.00) | 0.10 | 58.2 |
| Smoking | ||||
| Yes | 8 | 0.90 (0.70, 1.09) | 0.005 | 65.9 |
| No | 10 | 0.83 (0.72, 0.93) | 0.265 | 19.3 |
| Jadad | ||||
| 3 | 4 | 0.76 (0.56, 0.95) | 0.294 | 19.3 |
| 4 | 9 | 0.99 (0.86, 1.12) | 0.207 | 26.7 |
| 5 | 5 | 0.74 (0.59, 0.89) | 0.184 | 35.5 |
| IF | ||||
| > 3 | 9 | 0.84 (0.70, 0.98) | 0.171 | 30.9 |
| <3 | 9 | 0.87 (0.72, 1.03) | 0.007 | 62.2 |
| Study type | ||||
| Case-control | 11 | 0.89 (0.76, 1.02) | 0.021 | 52.3 |
| Cohort | 7 | 0.80 (0.62, 0.97) | 0.143 | 37.5 |
| Country | ||||
| USA | 8 | 0.83 (0.69, 0.97) | 0.178 | 31.3 |
| Denmark | 1 | 0.81 (0.48, 1.42) | 0 | 0 |
| Australia | 2 | 0.86 (0.49, 1.23) | 0.112 | 60.4 |
| Italy | 2 | 1.04 (0.75, 1.34) | 0.023 | 80.6 |
| Canada | 1 | 1.07 (0.64, 1.79) | 0 | 0 |
| Sweden | 1 | 0.54 (0.31, 0.91) | 0 | 0 |
| Taiwan, China | 1 | 0.79 (0.47, 1.32) | 0 | 0 |
| Netherlands | 1 | 0.65 (0.41, 1.03) | 0 | 0 |
| Geographical region | ||||
| Europe | 5 | 0.92 (0.70, 1.15) | 0.006 | 72.1 |
| Oceania | 3 | 0.77 (0.55, 0.99) | 0.210 | 36.0 |
| America | 9 | 0.84 (0.71, 0.98) | 0.211 | 26.2 |
| Asia | 1 | 0.79 (0.47, 1.32) | 0 | 0 |
IF, impact factor; No., Number; RR, relative risk; CI, confidence interval; USA, the United States of America; BMI, body mass index; OCP, oral contraceptive pill.
Figure 3Sensitivity analysis of tea consumption and risk of ovarian cancer showing that omission of any study did not alter the observed effect
Figure 4(A, B)Meta-regulation of study design and risk of ovarian cancer showing that study design was associated with a 47.90% heterogeneity reduction across the studies, and geographical region was associated with a 44.60% heterogeneity reduction across the studies.
Figure 5Begger's funnel plot assessing publication bias among the studies
Figure 6Egger's funnel plot assessing publication bias among the studies